ARKG - Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline Update | Benzinga
Cathie Wood-run Ark Invest on Friday picked up shares of a biopharma company after it revealed significant progress with it weight-loss drug candidate.
What Happened: Ark, through its ARK Genomic Revolution ETF (CBOE: ARKG), bought 11,360 shares of Amgen, Inc. (NASDAQ:AMGN), which rallied nearly 12% on Friday. The purchase would have been worth $3.54 million.
Following Friday’s purchase, Amgen’s weighting in ARKG stood at 1.06%, attributed to the 51,712 shares held by the exchange-traded fund.
See Also: Best ETFs To Buy Right Now
Why It’s ...